Nordeloz (Zoledronic Acid)

Zoledronic Acid, the active ingredient in Nordeloz, is a bisphosphonate presented as an intravenous formulation for infusion use. It is employed to treat bone‑related disorders such as osteoporosis, Paget's disease, bone metastases and hypercalcemia of malignancy in adult patients. GNH USA supplies Nordeloz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nordeloz is a bisphosphonate that acts on conditions characterized by excessive bone resorption. - Osteoporosis: reduces fracture risk by strengthening bone density. - Paget's disease of bone: normalises abnormal bone turnover and alleviates pain. - Bone metastases: limits skeletal complications and pain associated with cancer spread to bone. - Hypercalcemia of malignancy: lowers elevated calcium levels caused by malignant disease.

Adverse reactions may occur with intravenous bisphosphonate therapy.

Common Side Effects: - Acute phase reaction: fever, chills, myalgia. - Nausea or vomiting. - Headache. - Fatigue. - Transient elevation of serum creatinine.

Serious or Rare Side Effects: - Renal toxicity or acute kidney injury. - Severe hypocalcaemia. - Osteonecrosis of the jaw. - Atrial fibrillation or other cardiac arrhythmias. - Anaphylactic or severe allergic reactions.

Prior to administration, clinicians should evaluate patient‑specific risk factors. - Renal function assessment: ensure adequate glomerular filtration before infusion. - Serum calcium monitoring: correct hypocalcaemia before treatment. - Concomitant nephrotoxic drugs: avoid or adjust dosing when possible. - Hydration status: maintain adequate fluid intake to reduce renal stress. - Dental health: perform oral examination and treat infections before therapy. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Zoledronic Acid may interact with several medication classes.

Major Interactions (Avoid): - Concurrent use of other bisphosphonates or potent nephrotoxic agents (e.g., aminoglycosides). - High‑dose vitamin D or calcitriol that may precipitate hypercalcaemia. - Loop diuretics that increase renal calcium excretion.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can affect renal function. - Corticosteroids, which may exacerbate bone loss. - Calcium supplements or antacids containing aluminium/magnesium that can interfere with absorption.